Gene Expression Signatures as Biomarkers of Tumour Hypoxia

Clinical Oncology

Volumn 27, Issue 10, 2015, Pages 547-560

  Harris, B H L ^a   Barberis, A ^a   West, C M L ^b   Buffa, F M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Annotation; Gene signature; Hypoxia; Microarray; Radiation; Treatment stratification

Indexed keywords

BIOLOGICAL MARKER; TRANSCRIPTOME; TUMOR MARKER;

ARTICLE; CANCER RESISTANCE; GENE EXPRESSION; HUMAN; HYPOXIA; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR GENETICS; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; REPRODUCIBILITY; TREATMENT RESPONSE; TUMOR HYPOXIA; TUMOR VOLUME; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; NEOPLASM; PROCEDURES; PROGNOSIS;

BIOMARKERS, TUMOR; GENE EXPRESSION PROFILING; HUMANS; NEOPLASMS; PROGNOSIS; TRANSCRIPTOME; TUMOR HYPOXIA;

EID: 84941314335     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2015.07.004     Document Type: Article

References (103)

1. Vaupel P., Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007, 26(2):225-239.
2. Giatromanolaki A., Harris A.L. Tumour hypoxia, hypoxia signaling pathways and hypoxia inducible factor expression in human cancer. Anticancer Res 2001, 21(6B):4317-4324.
3. Moskwa P., Buffa F.M., Pan Y., et al. miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell 2011, 41(2):210-220.
4. Camps C., Buffa F.M., Colella S., et al. hsa-miR-210 is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res 2008, 14(5):1340-1348.
5. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
6. Semenza G.L. HIF-1: using two hands to flip the angiogenic switch. Cancer Metastasis Rev 2000, 19(1-2):59-65.
7. Chang Q., Jurisica I., Do T., et al. Hypoxia predicts aggressive growth and spontaneous metastasis formation from orthotopically grown primary xenografts of human pancreatic cancer. Cancer Res 2011, 71(8):3110-3120.
8. Pennacchietti S., Michieli P., Galluzzo M., et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003, 3(4):347-361.
9. Erler J.T., Cawthorne C.J., Williams K.J., et al. Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol Cell Biol 2004, 24(7):2875-2889.
10. Yotnda P., Wu D., Swanson A.M. Hypoxic tumors and their effect on immune cells and cancer therapy. Methods Mol Biol 2010, 651:1-29.
11. Bristow R.G., Hill R.P. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 2008, 8(3):180-192.
12. Harris A.L. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002, 2(1):38-47.
13. Brizel D.M., Sibley G.S., Prosnitz L.R., et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997, 38(2):285-289.
14. Tanaka N., Kato H., Inose T., et al. Expression of carbonic anhydrase 9, a potential intrinsic marker of hypoxia, is associated with poor prognosis in oesophageal squamous cell carcinoma. Br J Cancer 2008, 99(9):1468-1475.
15. Driessen A., Landuyt W., Pastorekova S., et al. Expression of carbonic anhydrase IX (CA IX), a hypoxia-related protein, rather than vascular-endothelial growth factor (VEGF), a pro-angiogenic factor, correlates with an extremely poor prognosis in esophageal and gastric adenocarcinomas. Ann Surg 2006, 243(3):334-340.
16. Dai C.X., Gao Q., Qiu S.J., et al. Hypoxia-inducible factor-1 alpha, in association with inflammation, angiogenesis and MYC, is a critical prognostic factor in patients with HCC after surgery. BMC Cancer 2009, 9:418.
17. Hung J.J., Yang M.H., Hsu H.S., et al. Prognostic significance of hypoxia-inducible factor-1alpha, TWIST1 and Snail expression in resectable non-small cell lung cancer. Thorax 2009, 64(12):1082-1089.
18. Schindl M., Schoppmann S.F., Samonigg H., et al. Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 2002, 8(6):1831-1837.
19. Trastour C., Benizri E., Ettore F., et al. HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome. Int J Cancer 2007, 120(7):1451-1458.
20. Milosevic M., et al. Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer. Clin Cancer Res 2012, 18(7):2108-2114.
21. Gray L.H., Conger A.D., Ebert M., et al. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953, 26(312):638-648.
22. Rippe B., Haraldsson B. Transport of macromolecules across microvascular walls: the two-pore theory. Physiol Rev 1994, 74(1):163-219.
23. Heldin C.H., Rubin K., Pietras K., et al. High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer 2004, 4(10):806-813.
24. Overgaard J. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res 1994, 6(10-11):509-518.
25. Stuben G., Pottgen C., Knuhmann K., et al. Erythropoietin restores the anemia-induced reduction in radiosensitivity of experimental human tumors in nude mice. Int J Radiat Oncol Biol Phys 2003, 55(5):1358-1362.
26. Aapro M., Spivak J.L. Update on erythropoiesis-stimulating agents and clinical trials in oncology. Oncologist 2009, 14(Suppl. 1):6-15.
27. Henke M., Laszig R., Rube C., et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003, 362(9392):1255-1260.
28. Chaplin D.J., Horsman M.R., Trotter M.J. Effect of nicotinamide on the microregional heterogeneity of oxygen delivery within a murine tumor. J Natl Cancer Inst 1990, 82(8):672-676.
29. Hoskin P.J., Rojas A.M., Bentzen S.M., et al. Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J Clin Oncol 2010, 28(33):4912-4918.
30. Janssens G.O., Rademakers S.E., Terhaard C.H., et al. Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial. J Clin Oncol 2012, 30(15):1777-1783.
31. Eustace A., Irlam J.J., Taylor J., et al. Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial. Radiother Oncol 2013, 108(1):40-47.
32. Overgaard J. Sensitization of hypoxic tumour cells - clinical experience. Int J Radiat Biol 1989, 56(5):801-811.
33. Cade I.S., McEwen J.B., Dische S., et al. Hyperbaric oxygen and radiotherapy: a Medical Research Council trial in carcinoma of the bladder. Br J Radiol 1978, 51(611):876-878.
34. Watson E.R., Halnan K.E., Dische S., et al. Hyperbaric oxygen and radiotherapy: a Medical Research Council trial in carcinoma of the cervix. Br J Radiol 1978, 51(611):879-887.
35. Overgaard J., Hansen H.S., Overgaard M., et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 1998, 46(2):135-146.
36. Kaanders J.H., Pop L.A., Marres H.A., et al. Accelerated radiotherapy with carbogen and nicotinamide (ARCON) for laryngeal cancer. Radiother Oncol 1998, 48(2):115-122.
37. Moese J.R., Moese G. Oncolysis by clostridia. I. Activity of Clostridium butyricum (M-55) and other nonpathogenic clostridia against the Ehrlich carcinoma. Cancer Res 1964, 24:212-216.
38. Malmgren R.A., Flanigan C.C. Localization of the vegetative form of Clostridium tetani in mouse tumors following intravenous spore administration. Cancer Res 1955, 15(7):473-478.
39. Carey R.W., Whang H.Y., Neter E., Bryant B. Clostridial oncolysis in man. Eur J Cancer 1967, 3:37-46.
40. Binley K., Askham Z., Martin L., et al. Hypoxia-mediated tumour targeting. Gene Ther 2003, 10(7):540-549.
41. Shibata T., Giaccia A.J., Brown J.M. Hypoxia-inducible regulation of a prodrug-activating enzyme for tumor-specific gene therapy. Neoplasia 2002, 4(1):40-48.
42. Hicks K.O., Myint H., Patterson A.V., et al. Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine. Int J Radiat Oncol Biol Phys 2007, 69(2):560-571.
43. Meng F., Evans J.W., Bhupathi D., et al. Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302. Mol Cancer Ther 2012, 11(3):740-751.
44. Liu S.K., Coackley C., Krause M., et al. A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia. Radiother Oncol 2008, 88(2):258-268.
45. Gunderson L.L. Clinical radiation oncology 2012, Elsevier Saunders, Philadelphia.
46. Thomson D., Yang H., Baines H., et al. NIMRAD - a phase III trial to investigate the use of nimorazole hypoxia modification with intensity-modulated radiotherapy in head and neck cancer. Clin Oncol (R Coll Radiol) 2014, 26(6):344-347.
47. Nordsmark M., Bentzen S.M., Rudat V., et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005, 77(1):18-24.
48. Nordsmark M., Overgaard M., Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996, 41(1):31-39.
49. Hockel M., Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001, 93(4):266-276.
50. Stone H.B., Brown J.M., Phillips T.L., et al. Oxygen in human tumors: correlations between methods of measurement and response to therapy. Summary of a workshop held November 19-20, 1992, at the National Cancer Institute, Bethesda, Maryland. Radiat Res 1993, 136(3):422-434.
51. Mason R.P. Non-invasive assessment of kidney oxygenation: a role for BOLD MRI. Kidney Int 2006, 70(1):10-11.
52. Favaro E., Lord S., Harris A.L., et al. Gene expression and hypoxia in breast cancer. Genome Med 2011, 3(8):55.
53. Chapman J.D., Franko A.J., Sharplin J. A marker for hypoxic cells in tumours with potential clinical applicability. Br J Cancer 1981, 43(4):546-550.
54. Chitneni S.K., Palmer G.M., Zalutsky M.R., et al. Molecular imaging of hypoxia. J Nucl Med 2011, 52(2):165-168.
55. Tuttle S.W., Maity A., Oprysko P.R., et al. Detection of reactive oxygen species via endogenous oxidative pentose phosphate cycle activity in response to oxygen concentration: implications for the mechanism of HIF-1alpha stabilization under moderate hypoxia. J Biol Chem 2007, 282(51):36790-36796.
56. Buffa F.M., Harris A.L., West C.M., et al. Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. Br J Cancer 2010, 102(2):428-435.
57. Ghazoui Z., Buffa F.M., Dunbier A.K., et al. Close and stable relationship between proliferation and a hypoxia metagene in aromatase inhibitor-treated ER-positive breast cancer. Clin Cancer Res 2011, 17(9):3005-3012.
58. Winter S.C., Buffa F.M., Silva P., et al. Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. Cancer Res 2007, 67(7):3441-3449.
59. Aebersold D.M., Burri P., Beer K.T., et al. Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 2001, 61(7):2911-2916.
60. Koukourakis M.I., Giatromanolaki A., Sivridis E., et al. Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin Cancer Res 2001, 7(11):3399-3403.
61. Schrijvers M.L., van der Laan B.F., de Bock G.H., et al. Overexpression of intrinsic hypoxia markers HIF1alpha and CA-IX predict for local recurrence in stage T1-T2 glottic laryngeal carcinoma treated with radiotherapy. Int J Radiat Oncol Biol Phys 2008, 72(1):161-169.
62. Le Q.T., Fisher R., Oliner K.S., et al. Prognostic and predictive significance of plasma HGF and IL-8 in a phase III trial of chemoradiation with or without tirapazamine in locoregionally advanced head and neck cancer. Clin Cancer Res 2012, 18(6):1798-1807.
63. Overgaard J., Eriksen J.G., Nordsmark M., et al. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol 2005, 6(10):757-764.
64. Lim A.M., Rischin D., Fisher R., et al. Prognostic significance of plasma osteopontin in patients with locoregionally advanced head and neck squamous cell carcinoma treated on TROG 02.02 phase III trial. Clin Cancer Res 2012, 18(1):301-307.
65. Peters D.G., Ning W., Chu T.J., et al. Comparative SAGE analysis of the response to hypoxia in human pulmonary and aortic endothelial cells. Physiol Genomics 2006, 26(2):99-108.
66. Ning W., Chu T.J., Li C.J., et al. Genome-wide analysis of the endothelial transcriptome under short-term chronic hypoxia. Physiol Genomics 2004, 18(1):70-78.
67. Bosco M.C., Puppo M., Santangelo C., et al. Hypoxia modifies the transcriptome of primary human monocytes: modulation of novel immune-related genes and identification of CC-chemokine ligand 20 as a new hypoxia-inducible gene. J Immunol 2006, 177(3):1941-1955.
68. Jogi A., Vallon-Christersson J., Holmquist L., et al. Human neuroblastoma cells exposed to hypoxia: induction of genes associated with growth, survival, and aggressive behavior. Exp Cell Res 2004, 295(2):469-487.
69. Aprelikova O., Wood M., Tackett S., et al. Role of ETS transcription factors in the hypoxia-inducible factor-2 target gene selection. Cancer Res 2006, 66(11):5641-5647.
70. Koong A.C., Denko N.C., Hudson K.M., et al. Candidate genes for the hypoxic tumor phenotype. Cancer Res 2000, 60(4):883-887.
71. Denko N.C., Fontana L.A., Hudson K.M., et al. Investigating hypoxic tumor physiology through gene expression patterns. Oncogene 2003, 22(37):5907-5914.
72. Manalo D.J., Rowan A., Lavoie T., et al. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 2005, 105(2):659-669.
73. Wang V., Davis D.A., Haque M., et al. Differential gene up-regulation by hypoxia-inducible factor-1alpha and hypoxia-inducible factor-2alpha in HEK293T cells. Cancer Res 2005, 65(8):3299-3306.
74. Detwiller K.Y., Fernando N.T., Segal N.H., et al. Analysis of hypoxia-related gene expression in sarcomas and effect of hypoxia on RNA interference of vascular endothelial cell growth factor A. Cancer Res 2005, 65(13):5881-5889.
75. Mense S.M., Sengupta A., Zhou M., et al. Gene expression profiling reveals the profound upregulation of hypoxia-responsive genes in primary human astrocytes. Physiol Genomics 2006, 25(3):435-449.
76. Chi J.T., Wang Z., Nuyten D.S., et al. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med 2006, 3(3):e47.
77. Elvidge G.P., Glenny L., Appelhoff R.J., et al. Concordant regulation of gene expression by hypoxia and 2-oxoglutarate-dependent dioxygenase inhibition: the role of HIF-1alpha, HIF-2alpha, and other pathways. J Biol Chem 2006, 281(22):15215-15226.
78. Seigneuric R., Starmans M.H., Fung G., et al. Impact of supervised gene signatures of early hypoxia on patient survival. Radiother Oncol 2007, 83(3):374-382.
79. Shi Y.F., Fong C.C., Zhang Q., et al. Hypoxia induces the activation of human hepatic stellate cells LX-2 through TGF-beta signaling pathway. FEBS Lett 2007, 581(2):203-210.
80. Sung F.L., Hui E.P., Tao Q., et al. Genome-wide expression analysis using microarray identified complex signaling pathways modulated by hypoxia in nasopharyngeal carcinoma. Cancer Lett 2007, 253(1):74-88.
81. Beyer S., Kristensen M.M., Jensen K.S., et al. The histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-inducible factor HIF. J Biol Chem 2008, 283(52):36542-36552.
82. van Malenstein H., Gevaert O., Libbrecht L., et al. A seven-gene set associated with chronic hypoxia of prognostic importance in hepatocellular carcinoma. Clin Cancer Res 2010, 16(16):4278-4288.
83. Benita Y., Kikuchi H., Smith A.D., et al. An integrative genomics approach identifies Hypoxia Inducible Factor-1 (HIF-1)-target genes that form the core response to hypoxia. Nucleic Acids Res 2009, 37(14):4587-4602.
84. Fardin P., Barla A., Mosci S., et al. The l1-l2 regularization framework unmasks the hypoxia signature hidden in the transcriptome of a set of heterogeneous neuroblastoma cell lines. BMC Genomics 2009, 10:474.
85. Hu Z., Fan C., Livasy C., et al. A compact VEGF signature associated with distant metastases and poor outcomes. BMC Med 2009, 7:9.
86. Fardin P., Barla A., Mosci S., et al. A biology-driven approach identifies the hypoxia gene signature as a predictor of the outcome of neuroblastoma patients. Mol Cancer 2010, 9:185.
87. Sorensen B.S., Toustrup K., Horsman M.R., et al. Identifying pH independent hypoxia induced genes in human squamous cell carcinomas in vitro. Acta Oncol 2010, 49(7):895-905.
88. Ghorbel M.T., Cherif M., Jenkins E., et al. Transcriptomic analysis of patients with tetralogy of Fallot reveals the effect of chronic hypoxia on myocardial gene expression. J Thorac Cardiovasc Surg 2010, 140(2):337-345.
89. Toustrup K., Sorensen B.S., Nordsmark M., et al. Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer. Cancer Res 2011, 71(17):5923-5931.
90. Starmans M.H., Chu K.C., Haider S., et al. The prognostic value of temporal in vitro and in vivo derived hypoxia gene-expression signatures in breast cancer. Radiother Oncol 2012, 102(3):436-443.
91. Eustace A., Mani N., Span P.N., et al. A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer. Clin Cancer Res 2013, 19(17):4879-4888.
92. Pubmed, 2015. Available at: http://www.ncbi.nlm.nih.gov/pubmed.
93. Elsevier. Scopus, 2015. Available at: http://www.scopus.com/.
94. Reuter's. Web of Science, 2015. Available at: http://apps.webofknowledge.com/UA_GeneralSearch_input.do?product=UA&search_mode=GeneralSearch&SID=T1qM9QTDnrYLU9prd3h&preferencesSaved=.
95. Khurana P. HypoxiaDB, 2015. Available at: http://www.hypoxiadb.com/.
96. Harvard University. GeneSigDB, 2015. Available at: http://compbio.dfci.harvard.edu/genesigdb/.
97. Blick C., Ramachandran A., Wigfield S., et al. Hypoxia regulates FGFR3 expression via HIF-1alpha and miR-100 and contributes to cell survival in non-muscle invasive bladder cancer. Br J Cancer 2013, 109(1):50-59.
98. Favaro E., Ramachandran A., McCormick R., et al. MicroRNA-210 regulates mitochondrial free radical response to hypoxia and Krebs cycle in cancer cells by targeting iron sulfur cluster protein ISCU. PLoS One 2010, 5(4):e10345.
99. Ramachandran A., Betts G., Bhana S., et al. An in vivo hypoxia metagene identifies the novel hypoxia inducible factor target gene SLCO1B3. Eur J Cancer 2013, 49(7):1741-1751.
100. Masiero M., Simoes F.C., Han H.D., et al. A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis. Cancer Cell 2013, 24(2):229-241.
101. Starmans M.H., Pintilie M., John T., et al. Exploiting the noise: improving biomarkers with ensembles of data analysis methodologies. Genome Med 2012, 4(11):84.
102. Fox N.S., Starmans M.H., Haider S., et al. Ensemble analyses improve signatures of tumour hypoxia and reveal inter-platform differences. BMC Bioinformatics 2014, 15:170.
103. Betts G.N., Eustace A., Patiar S., et al. Prospective technical validation and assessment of intra-tumour heterogeneity of a low density array hypoxia gene profile in head and neck squamous cell carcinoma. Eur J Cancer 2013, 49(1):156-165.